While adjusting its target price from 85 to 86 euros, Stifel reiterates its 'hold' recommendation on Equasens, showing a preference for its peers Nexus and CompuGroup, both recommended at 'buy', in the healthcare IT sector.

Equasens reported solid sales for the first quarter, with organic growth of 14% (+11.1% excluding the Segur digitization plan in France)", he pointed out after the trading update.

The broker raises its organic growth assumption for 2023 from 6.1% to 6.4%, but 'remains cautious insofar as business can be bumpy, and bases for comparison will become increasingly difficult this year'.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.